2Ziegler D, Hanefeld M, Ruhnau KJ, et al. and the ALAD IN I// Study Group. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid:A 7-monthmulti-center randomized controlled trial( ALAD INⅢ Study). Diabetes Care 1999;22:1296- 1301.
4Tawata M, Nitta K, Kurihara A, et al. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropa-thy. Prostaglandins 1995 ;49 ( 1 ) :27-39.
5Srivastava S, Ramana KV, Tammali R, et al. Contribution of aldose reductase to diabetic hyperoliferation of vascular smooth muscel cells. Diabetes 2006;55(4) :901-910.
6Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy : A randomized controlled trial, rhNGF Clinical Investi- gator Group. JAMA 2000 ;284(17) :2215-2221.
